Evidence map›Paper›PMID 23954168›Full record

ReviewTrends in molecular medicine2013

Is CD69 an effective brake to control inflammatory diseases?

Roberto González-Amaro, José R Cortés, Francisco Sánchez-Madrid, Pilar Martín

Abstract readReview
In one paragraph

Review in Trends in molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. ZIP3 is essential for the encephalitogenic function of pTh17 cells by regulating intracellular zinc levels.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2026
    Article
  12. A viral glycoprotein targets IgGEMBO molecular medicine · 2026
    Article
  13. Article
  14. Progenitor CD8Apoptosis : an international journal on programmed cell death · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Roberto González-AmaroDepartment of Immunology, School of Medicine, UASLP, San Luis Potosí, México.
José R Cortés
Francisco Sánchez-Madrid
Pilar Martín
Spanish National Centre for Cardiovascular Research · ESUniversidad Autónoma de Madrid · ES

Funding

European Research Council 294340
6 · The paper itself

Abstract

Early studies described CD69 as a leukocyte activation marker, and suggested its involvement in the activation of different leukocyte subsets as well as in the pathogenesis of chronic inflammation. However, recent investigations have showed that CD69 knockout mice exhibit an enhanced or reduced susceptibility to different experimental models of inflammatory diseases, including those mediated by T helper 17 (Th17) lymphocytes. In this regard, the expression of CD69, both in Th17 lymphocytes and by a subset of regulatory T cells, has an important role in the control of the immune response and the inflammatory phenomenon. Therefore, different evidence indicates that CD69 exerts a complex immunoregulatory role in humans, and that it could be considered as a target molecule for the therapy of immune-mediated diseases.

Indexed as

AnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteAutoimmune DiseasesCD69 AntigensHumansHypersensitivityImmunomodulationInflammationLectins, C-TypeT-Lymphocytes, RegulatoryAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensLectins, C-TypeCD69immunoregulationinflammatory diseasesTh17 lymphocytesTreg lymphocytes

Identifiers

PMID23954168
PMCPMC4171681
OpenAlexW2086655007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.